JAKARTA - The results of the Nusantara Vaccine clinical trial initiated by Lieutenant General TNI (Ret.) Prof. Dr. dr. Terawan Agus Putranto, SpRad(K) published in an international medical journal.
The results of the clinical trial were published in the journal Human vaccines & Immunotherapeutics, which was indexed in Scopus.Scopus is a journal that has a high impact and is published under strict selection.
The article entitled "A personal COVID-19 dendritic cell vaccine made at point-of-care: Feasibility, safety, and antigenspecific cellular immunity was released on August 26, 2022.
In the introductory article, the induction of neutralizing antibodies for immediate protection is the emphasis of the initial report on the COVID-19 vaccine currently available. However, there is an increase in interest in the response of T-cells associated with this product.
It was then written, stated the purpose of the study. First, determine the feasibility of preparing a personal dendritic cell vaccine for a spike protein of SARS-CoV-2 at the treatment point. Second, set short-term security after the single subcution vaccine injection.
Then third, determine the specific immune response of antigen after vaccination, and fourth choose the formulation you like for future trials. The complete article on the results of clinical trials of the Nusantara Vaccine can be seen at wwww.tandfonline.com/doi/full/10,1080/21645515.2022.2100189
The Nusantara vaccine was developed with a dendritic cell approach. The way it works, everyone will take blood samples and then be presented with a vaccine kit formed from dendritic cells.
Furthermore, cells that are familiar with antigens will be incubated for 3-7 days.
The results will be injected back into the body. Inside the body, these dendritic cells are expected to trigger other immune cells to form a memory defense system against SARS CoV-2.
To note, the results of clinical trials I and II of the Nusantara Vaccine are the first clinical trials to enter an international medical journal in collaboration with Indonesia and America.
Previously, the development of the Nusantara Vaccine had also been published in the same journal with the title \'Dendritic cell vaccine as a potential strategy to end the COVID-19 pandemic. Why should it be Ex Vivo?' which was released on May 26, 2022.
Responding to this above, the founder of the Beranda Ruangan Discussion which is also a media practitioner, Dar Edi Yoga, welcomed and hoped that the government would immediately issue regulations for the Nusantara Vaccine.
"With the issuance of clinical trials of the Nusantara Vaccine in the national Human vaccines & Immunotherapeutics which were indexed in Scopus Q 1, it proves that the Nusantara Vaccine is not an fake vaccine," said Dar Edi Yoga.
According to him, the results of the Nusantara Vaccine clinical trial became the first clinical trial to be included in an international health media journal in handling the current COVID-19 outbreak.
"The Nusantara vaccine has been published in the SCOPUS Scientific Journal with a very high impact factor of 8,34. It shows the results of a very strict selection by Scopus," said Dar Edi Yoga.
The English, Chinese, Japanese, Arabic, and French versions are automatically generated by the AI. So there may still be inaccuracies in translating, please always see Indonesian as our main language. (system supported by DigitalSiber.id)
